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The knowledge of anything, since all things have causes, is not 
acquired or complete unless it is known by its causes. 
Avicenna 
  
  
ABSTRACT 
Diabetes is a common and increasing public health problem. Knowledge of risk factors is a 
prerequisite for efficient prevention; such knowledge is extensive for type 2 diabetes but 
limited for autoimmune forms of diabetes. LADA-latent autoimmune diabetes in adults is an 
autoimmune form of diabetes that develops in adults and has features of both type 1 and type 
2 diabetes. It accounts for relatively large proportion of all diabetes patients, yet risk factors 
are largely unexplored. The aim of this thesis was to investigate the influence of tobacco 
exposure and alcohol consumption on the risk of LADA, and also to explore these factors in 
relation to type 2 diabetes, to compare the etiology of these adult onset forms of diabetes.  
Analyses were based on data from two large Scandinavian population-based studies; the 
Norwegian HUNT-study, a prospective cohort study conducted between 1984 and 2008, and 
ESTRID, an ongoing Swedish case-control study with incident cases. Information on lifestyle 
including alcohol consumption and tobacco use was collected by questionnaire. Cases of 
diabetes were identified by self-report (HUNT) or through the health care system (ESTRID). 
Patients with LADA had onset ≥35 years and were glutamic acid decarboxylase autoantibody 
(GADA) positive. Information on lack of insulin treatment (HUNT) or C-peptide levels 
(ESTRID) were used to indicate a slow onset.  
Alcohol consumption was associated with reduced risk of LADA in both HUNT and 
ESTRID. In ESTRID, stratification by GADA levels indicated that the reduced risk primarily 
pertained to LADA with low GADA levels (odds ratio [OR] 0.85, 95% confidence interval 
[CI] 0.76–0.94 for every 5-gram increase in daily alcohol intake). Smoking was associated 
with a reduced risk of LADA in HUNT which we could not confirm in ESTRID; in contrast 
we found an increased risk of LADA in heavy smokers (OR; 1.37, 95% CI; 1.02-1.84). With 
regard to type 2 diabetes, we could confirm that alcohol intake is associated with a reduced 
risk and smoking with an increased risk. There was no association between moist snuff use 
and type 2 diabetes or LADA in either the Swedish (type 2 diabetes: OR for >10 box-years; 
1.00, 95% CI; 0.47-2.11, and LADA: 1.01, 95% CI; 0.45-2.29) or the Norwegian study. 
In conclusion, the results suggest that alcohol consumption reduces the risk of type 2 diabetes 
and type 2-like LADA. An increased risk of LADA was seen in smokers but results were 
contradictory and require further exploration. Finally the use of moist snuff was associated 
neither with type 2 diabetes nor LADA. These findings indicate that the etiology of LADA in 
part may be shared with type 2 diabetes and involve factors related to insulin sensitivity. 
Furthermore, they indicate that LADA may to some extent be preventable by lifestyle 
modification. 
   
  
  
SAMMANFATTNING PÅ SVENSKA  
Diabetes är en vanligt förekommande sjukdom och ett växande folkhälsoproblem. För 
effektiv prevention krävs kunskap om riskfaktorer; sådan kunskap finns för typ 2 diabetes 
men är mycket begränsad för autoimmuna former av sjukdomen. LADA – latent autoimmun 
diabetes hos vuxna – är en autoimmun form av diabetes som drabbar vuxna och som har drag 
av både typ 1 och typ 2 diabetes. LADA utgör en förhållandevis stor del av all diabetes, men 
trots detta är riskfaktorerna i princip okända. Syftet med denna avhandling var att studera hur 
tobak och alkoholkonsumtion påverkar risken att utveckla LADA, samt att undersöka dessa 
exponeringar avseende risken för typ 2-diabetes för att därigenom kunna jämföra etiologin 
för dessa två diabetesformer.  
Analyserna är baserade på data från två stora, populationsbaserade studier i Skandinavien; 
norska HUNT-studien, en prospektiv kohortstudie med data insamlad 1984-2008, och 
ESTRID, en pågående svensk fall-kontrollstudie med incidenta fall. Information om 
alkoholvanor, tobaksvanor, och andra livsstilsfaktorer samlades in genom frågeformulär. 
Fallen identifierades genom självrapporterad diabetes (HUNT) eller via sjukvården 
(ESTRID). LADA-patienterna var ≥35 år vid diagnos samt positiva för GADA 
(autoantikroppar mot glutaminsyredekarboxylas). Information om insulinberoende (HUNT) 
eller C-peptidnivåer (ESTRID) användes som indikation på långsam sjukdomsprogression.  
Alkoholkonsumtion var associerat med minskad risk för LADA i både HUNT och ESTRID. 
Stratifiering på GADA-nivåer indikerade att den minskade risken framför allt var kopplad till 
LADA med låga nivåer av GADA (oddskvot [OR] 0.85, 95 % konfidensintervall [CI] 0.76–
0.94 per 5 grams ökning i daglig konsumtion). Rökning var associerat med minskad risk för 
LADA i HUNT vilket dock inte kunde konfirmeras i ESTRID; tvärtom fann vi en ökad risk 
för LADA bland de som rökte mest (OR 1.37, 95 % CI 1.02-1.84). För typ 2 diabetes kunde 
vi bekräfta att alkoholkonsumtion är associerat med minskad risk medan rökning är kopplat 
till ökad risk. Vi fann inget samband mellan snus och risken för typ 2 diabetes eller LADA, 
varken i svenska ESTRID (OR för >10 box-years, typ 2 diabetes: 1.00, 95% CI; 0.47-2.11, 
LADA: 1.01, 95% CI; 0.45-2.29) eller i norska HUNT. 
Sammanfattningsvis tyder resultaten på att alkoholkonsumtion minskar risken för typ 2 
diabetes och typ 2 liknande LADA (låg-GADA). En ökad risk för LADA syntes bland 
rökare, men resultaten var motsägelsefulla och detta behöver utforskas vidare. Slutligen fanns 
inget samband mellan snus och risk för varken typ 2 diabetes eller LADA. Tillsammans tyder 
dessa fynd på att etiologin för LADA delvis liknar den för typ 2 diabetes och innefattar 
faktorer relaterade till insulinkänslighet. Vidare tyder de på att LADA till viss del skulle 
kunna förebyggas genom livsstilsförändringar. 
  
 NAISREP NI TCARTSBA
 چکیده به فارسی
های جدی برای جامعه، افراد، و سیستم بهداشتی به دنبال دارد. متٔاسفانه دیابت  ترین بیماریهای مزمن به شمار میرود که پیامد از شایع  دیابت یکی
 ۲ع باشد. شناختن عوامل خطر شرط لازم برای پیشگیری کارآمد است. بسیاری از عوامل خطر دیابت نو  قابل پیشگیری می  دارمان ندارد، ولی
 یک فرم خود ایمنی از دیابت   ADALبیماری باشد. شناخته شده هستند، در صورتیکه چنین دانشی در مورد نوع خود ایمنی دیابت محدود می
 کلیه بیماران ۹%باشد و شامل  بالا می  باشد. با اینکه شیوع آن می ۲و  ۱دیابت  نوع های هر دو که در بزرگسالی رخ میدهد و دارای ویژگی  است
باشند. هدف این پایان نامه مطالعه تاثیر مصرف الکل و دخانیات  تا حد زیادی ناشناخته می  دیابتی در بزرگسالی میشود، ولی هنوز عوامل خطر آن
  دو فرمنیز مورد مطالعه قرار گرفت، تا به مقایسه اتیولوژی این  ۲اثر این عوامل در بروز دیابت نوع  باشد. همچنین می  ADALدر بروز بیماری
 .دیابت در بزرگسالی بپردازد
مطالعه، یک مطالعه کوهورت اولین   باشد؛ بر جمعیت اسکاندیناوی می  مطالعه بزرگ مبتنی ۲این پایان نامه، براساس اطلاعات به کار گرفته شده از
 باشد. می یک مطالعه مورد شاهدی سوئدی  ,DIRTSE و دومی  TNUHبه نام 4891(-8002( پیگیری سال ۲۲با  نروژیآینده نگر 
اطلاعات مربوط به شیوه زندگی از جمله مصرف الکل و تنباکو توسط پرسشنامه جمع آوری شد. موارد ابتلا به دیابت توسط خود گزارش 
داشتند و  سال سن ۳۵بیماران دیابتی که بیشتر از  مشخص شدند.  )DIRTSE() و یا از طریق سیستم مراقبت های بهداشتیTNUH(
اطلاعات .  طبقه بندی شدند  ADALمثبت بودند به عنوان ((گلوتامیک اسید دکربوکسیلاز اتوآنتی بادی   itnA- DAGعلاوه بر این
  ADALجدا کردن بیمارانبرای  C )DIRTSE(-  editpep) و یا سطحTNUHبا انسولین (  زودهنگام درمان  شروعمربوط به عدم 
 . استفاده شد ۱از دیابت نوع 
با  ADALهمراه بود. طبقه بندی کردن بیماران   DIRTSEو   TNUHمطالعهدر هر دو   ADALمصرف الکل با کاهش خطر ابتلا
 sddOمرتبط است، نسبت شانس (  ADAGبا سطوح پایین  ADALنشان داد که کاهش خطر در درجه اول در بیماران ADAG سطح
بود.  67.0-49.0 )IC ,lavretnI ecnedifnoCبا فاصله اطمینان ( 48.0  صرف روزانهگرم در م  ۳) برای افزایش هر oitaR
این تأیید نشد،  DIRTSE مرتبط است، گرچه در مطالعه ADAL نشان داد که سیگار کشیدن با کاهش خطر TNUH مشاهدات ما در
مطالعه ما در  .)48.1-20.1 ;IC ;73.1 ;RO( در افرادی که مصرف سیگار بالا داشتند مشاهده شد ADAL و حتی افزایش خطر
هیچ ارتباطی همراه است.  ۲تأیید کرد که مصرف الکل با کاهش خطرو سیگار کشیدن با افزایش خطر ابتلا به دیابت نوع   راستای مطالعات قبلی
 .  در مطالعات ما دیده نشد  ADALیا  ۲(انفیه مرطوب سوئدی ) و دیابت نوع  ffuns tsiomبین استفاده 
 را کاهش می دهد. افزایش خطر ابتلا به  ADALو  ۲، نتایج ما نشان می دهد که مصرف الکل خطر ابتلا به دیابت نوع  بطور خلاصه
  ADAL اتیولوژی.  این یافته ها نشان می دهد که داردبیشتر مطالعات در افراد سیگاری دیده شد اما نتایج متناقض بود و نیاز به  ADAL
ممکن است با   ADALو مرتبط با حساسیت به انسولین باشد.  به علاوه، نتایج نشان می دهد که ۲دیابت نوع  اتیولوژی  بامشابه ممکن است 
 .اصلاح شیوه زندگی تا حدی قابل پیشگیری باشد
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1 INTRODUCTION 
Diabetes is a chronic disease that occurs when the body cannot produce enough insulin and/or 
use insulin efficiently. It affects more than 415 million individuals globally, and the 
prevalence is expected to rise 50% by the year 2040. Diabetes contributes considerably to the 
burden of morbidity and is estimated to be the 7th leading cause of death (1; 2). At present, 
there is no cure for diabetes, as such prevention and management of the disease are crucial in 
order to reduce morbidity. Knowledge about risk factors is a necessity for successful 
preventive action. Such knowledge is extensive for type 2 diabetes but limited for 
autoimmune forms of diabetes. 
Latent autoimmune diabetes in adults (LADA) is described as a hybrid form of diabetes with 
features of both type 1 and type 2 diabetes (3). Like type 1 diabetes, it is characterized by 
presence of autoantibodies against pancreatic β-cells (3), but like type 2 diabetes it develops 
in adults and is afflicted with insulin resistance. Recent findings suggest that LADA accounts 
for 5% of all diabetes, and is almost as frequent as type 1 diabetes (4).  Risk factors are 
largely unexplored; but considering LADA as a mix of type 1 and type 2 diabetes, one could 
hypothesize that risk factors may include factors triggering autoimmunity and/or insulin 
resistance. 
The aim of this thesis was to investigate the risk of LADA in relation to alcohol consumption 
and tobacco use, two modifiable risk factors associated with type 2 diabetes. Analyses were 
based on data from a Norwegian cohort study and a Swedish case-control study, the largest 
population-based studies of LADA to date. The overall aim was to contribute to the 
understanding of the etiology of LADA. 
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2 BACKGROUND 
Diabetes mellitus is a chronic disease characterized by hyperglycemia, but it is a 
heterogeneous group of disorders with different pathologies: disturbances in insulin secretion, 
insulin sensitivity, or both (5). Diabetes is one of the world´s fastest increasing diseases; 
between 2000 and 2015 the number of individuals with diabetes increased from 171 to 415 
million worldwide and a further increase to 642 million affected individuals is project by 
2040 (1). This rise is projected to be most pronounced in Africa and Middle Eastern countries 
and the driving forces are aging populations, nutritional transition, and increasing prevalence 
of obesity and physical inactivity (1; 6). According to a new report from the International 
Diabetes Federation (IDF), 9.1% of the adult population (59.8 million) in Europe lives with 
diabetes (1), and in Sweden, 6.8% of adults are affected (7).  
Long-term exposure to abnormal high blood glucose can result in damages to blood vessels, 
heart, kidney and nerves (8); which are associated with premature death, primarily from 
cardiovascular diseases (1). In many  high income countries, diabetes is the primary cause of 
cardiovascular disease, blindness, nephropathy, and foot/leg amputation (1). Despite 
improvements in treatment and risk factor control, patient with diabetes still have excess 
mortality compared to the general population. In a report based on the Swedish National 
Diabetes Register, type 1 diabetes patients had twice the risk of death from any cause or 
cardiovascular disease compared to matched controls (9), and patients with type 2 diabetes 
had 27% higher risk of death from any cause and 33% from cardiovascular diseases, and the 
risk was substantially higher in patients with poor glycemic control (10)  
Diabetes and its complications pose an enormous burden on individuals, families, health 
systems, and public spending (1). At present diabetes cannot be cured, therefore prevention 
and control of diabetes is needed. A better understanding of the potential role of lifestyle 
factors in the etiology of diabetes is important for shaping effective diabetes prevention 
programs and also contributes to a better understanding of the pathogenesis of the disease. 
2.1 DIAGNOSIS OF DIABETES 
Hyperglycemia is the hallmark of diabetes. Plasma glucose (fasting and 2-hour plasma 
glucose) and HbA1c are the basis of diabetes diagnostic criteria (11; 12): 
- Fasting Plasma Plucose (FPG); ≥7.0 mmol/L, or 
- 2-Hour Plasma Glucose (2-h PG) value after a 75-g oral glucose tolerance test 
(OGTT): ≥11.1 mmol/L, or 
- Random plasma glucose: ≥11.1 mmol/L, together with classical symptoms of 
hyperglycemia, or 
- HbA1c: ≥6.5% 
 4 
The latest criterion of HbA1c, is however, not appropriate for diagnosis of diabetes in 
children and adolescents, some ethnicities, e.g. African Americans, gestational diabetes, and 
individuals with anemia and hemoglobinopathies (11).  
2.2 CLASSIFICATION OF DIABETES 
In 1985, diabetes was classified by WHO into two groups based on age and insulin 
dependency; insulin requiring diabetes mellitus (IDDM) and non-insulin requiring diabetes 
mellitus (NIDDM) (13). This classification was eventually considered inadequate, as not all 
IDDM patients became insulin deficient at diagnosis nor could all NIDDM patients be treated 
without insulin therapy (14). Later in 1999, diabetes was classified on basis of etiologies 
rather than degree of insulin deficiency, and IDDM and NIDDM were replaced by type 1 (β-
cell destruction) and type 2 diabetes (insulin resistance/relative insulin deficiency). In clinical 
practice, general observations of clinical phenotypes such as age at onset, apparent abruptness 
of onset of hyperglycemia, BMI, presence of ketosis, and immediate need for insulin 
treatment are the first tools for differentiating between diabetes types (15). It has been argued 
that the current subdivision of diabetes into type 1 and type 2 is, particularly in adults, an 
oversimplification of a spectrum of phenotypes spanning different subtypes of diabetes (16) 
with different degrees of overweight, insulin resistance, autoimmunity, metabolic syndrome 
and genetic susceptibility to HLA haplotypes. In this context, type 1 and type 2 diabetes are 
considered two extreme ends of the diabetes spectrum (figure 1). LADA-latent autoimmune 
diabetes in adults, first mentioned in 1993 by Tuomi et al (16),  is an example of an 
intermediate diabetes form with clinical and genetic feature of both type 1 and type 2 
diabetes, (3; 17-20).  
Figure 1. The spectrum of diabetes includes immune changes, age, HLA genetic 
susceptibility, BMI, and insulin therapy according to type of diabetes. Partly adapted from 
Leslie D. et al. (21) 
 
  5 
2.2.1 Type 2 diabetes 
Type 2 diabetes is the most prevalent form of diabetes and accounts for approximately 70-
90% of all cases of diabetes (2; 4; 11). In type 2 diabetes, hyperglycemia is typically caused 
by a combination of insulin resistance and impaired insulin secretion. When the β-cells lose 
the ability to release adequate insulin to compensate for insulin resistance, hyperglycemia 
becomes manifest. Insulin resistance is closely linked to obesity, and the increase in the 
prevalence of type 2 diabetes reported since the 1990s coincides with a worldwide rise in 
prevalence of obesity (22; 23). Progress of type 2 diabetes develops slowly through stages of 
pre-diabetes. Onset of type 2 diabetes typically occurs in middle-aged people or elderly, but 
the incidence is increasing in younger age groups (5). Type 2 diabetes is often managed 
initially with dietary and lifestyle changes, and if hyperglycemia is not sufficiently controlled, 
by oral lowering glucose medications (Metformin, and Sulfonylurea). Injectable insulin is 
required in patients who do not achieve glycemic control by oral tablet therapy (1; 24-26).  
Genetic risk factors 
Type 2 diabetes results from the complex interplay between genetic, epigenetic, and 
environmental factors (27). It is partly an inherited disease; the risk is two to six times higher 
in individuals with family history of diabetes (28-30). Twin studies have shown that the 
concordance rate for identical twins is 35-80% and 15-35% for non-identical twins (31-35); 
indicating a strong genetic component. Unlike type 1 diabetes for which the genetic risk is 
mainly related to the HLA region, the genetic component of type 2 diabetes appears to be 
scattered all across genome. Type 2 diabetes is a polygenic disease, and more than 120 
genetic variants and >80 loci have been thus far associated with type 2 diabetes (27; 36). 
However, these variants explain only a small fraction (20%) of the total heritability of type 2 
diabetes (27; 36). Most of the genes associated with type 2 diabetes are involved in 
development, function, or regulation of β-cells including TCF7L2, SLC30A8, and KCNQ1 
and only a few genes are involved in insulin resistance like PPARG gene, and obesity 
susceptibility locus FTO. The strongest genetic risk factor for type 2 diabetes so far is the 
TCF7L2 rs7903146 variant (37-39)  
Environmental risk factors 
Overweight and obesity are major risk factors for type 2 diabetes, by way of promoting 
insulin resistance (22). Physical inactivity is also recognized as an important risk factor for 
both obesity and type 2 diabetes. Not only excessive calorie intake but also low quality diet 
characterized by high glycemic load; trans fatty acids, low fiber content is associated with 
increased risk of type 2 diabetes (22). Moderate alcohol intake is associated with a reduced 
risk of type 2 diabetes (40), primarily by way of improving insulin sensitivity and smoking is 
an established risk factors for type 2 diabetes by way of impairing insulin sensitivity (41). 
There is also some evidence suggesting that exposure to environmental toxins such as arsenic 
and persistent organic pollutants might be associated with increased risk of type 2 diabetes  
(42). Intervention studies show that the risk of type 2 diabetes can be reduced by lifestyle 
 6 
modification including weight loss and regular physical activity (43). Estimation of 
population-attributable risks (PAR) in observational studies suggests that the majority (72% 
to 91%) of type 2 diabetes cases can be prevented by adherence to a healthy lifestyle 
including maintaining normal weight, being physical active, having a healthy diet, and 
refraining from smoking (44-46).  
2.2.1 Type 1 diabetes  
In type 1 diabetes, β-cell destruction leads to an absolute defect in pancreatic function, which 
results in inability to produce adequate amounts of insulin, and insulin treatment must be 
provided, since most of  β-cells are destroyed (47). Type 1 diabetes accounts for 8-10% of all 
diabetes patients (4; 47). Europe, particularly the Nordic countries, has the highest incidence 
of type 1 diabetes in children and adolescents (1). Type 1 diabetes accounts for the vast 
majority of diabetes in children but type 1 diabetes can develop at any age (48).  
Genetic risk factors 
Familial aggregation studies support the importance of both genetic and environmental risk 
factors in the development of type 1 diabetes (49). Among all newly diagnosed type 1 
diabetes patients, 10-15% have positive family history of type 1 diabetes (50; 51), and in 
siblings of affected individuals, the risk of type 1 diabetes is increased 15-fold (51). The 
concordance rate for identical twins (20-50%) is higher than in non-identical twins (5-10%); 
suggesting there is a strong genetic component for type 1 diabetes (31; 32; 52-54). About 
50% of susceptibility is inherited in HLA haplotypes (DQA1*03:01-DQB*03:02 [DQ8] and 
DQA1*05:01-DQB1*02:01[DQ2]), and to a lesser extent in non-HLA loci including the 
insulin gene (27; 55). Estimates from candidate-gene and GWAS studies indicated that the 
identified variants combined could explain around 75% of heritability of type 1 diabetes (56; 
57). 
Environmental risk factors 
Tremendous effort has been put into identifying environmental triggers of autoimmunity 
through studies like the TEDDY (58), but so far, very few environmental factors have 
consistently been linked to development of type 1 diabetes. Potential environmental triggers 
that may initiate autoimmunity or precipitate β-cells destruction included exposure to 
maternal infection during pregnancy, environmental pollutants, infection, early life exposure 
to cow milk, socioeconomic factors, and  low exposure to environmental microorganisms (the 
hygiene hypothesis) (59-66).  
2.2.2 Latent autoimmune diabetes in adults (LADA)  
The term LADA was introduced for the first time in 1993 by Tuomi et al to define a slowly 
progressing form of autoimmune diabetes that occurred in adulthood and could be treated 
initially without insulin (16). Earlier, Irvine et al (1977) also identified a group of patients 
who had originally been diagnosed as type 2 diabetes but who were also positive for islet cell 
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antibodies (67), and Groop et al (1986) described a group of adult patients with a latent form 
of type 1 diabetes (68). There is no consensus, so far, on the concept of LADA; some 
continue to consider it type 2 diabetes with positive autoantibodies (69), whereas others 
including WHO (5; 15; 70) describe it as a slowly progressing form of type 1 diabetes (71; 
72). Knowledge on risk factors may help to clarify to what extent LADA shares features of 
type 1 vs type 2 diabetes and whether it is useful to consider it as a separate form of diabetes. 
LADA is considered a hybrid between type 1 and type 2 diabetes, and some have even 
termed it type 1.5 diabetes (73; 74). LADA patients are insulin resistant and overweight but 
less pronounced than type 2 diabetes patients and they have better lipid and metabolic profile 
(19; 75-77). Besides, the insulin requirement in LADA patients is less pronounced and C-
peptide levels are higher compared with type 1 diabetes (17; 19; 78). Also, some of the risk 
factors for LADA so far identified are similar to those of type 2 diabetes (79-83), but not all 
(84-86). Genetic findings also support the view of LADA as a hybrid, with genetic features of 
both type 1 and type 2 diabetes (20; 87).  
LADA is a common, accounting for about 9% of all patients are initially diagnosed as type 2 
diabetes patients (88). However, the prevalence varies by population, ethnicity, and the 
diagnostic criteria used to define LADA. The estimated prevalence of LADA is around 9% in 
China (89). In a new Swedish study, ANDIS (All New Diabetics in Scania), all incident cases 
of diabetes in the county of Scania, are classified according to diabetes type based on clinical 
and genetic features. Since 2008, 10,226 patients have been included and of those, LADA 
account for 4.8% of all diabetes patients in children and adults (figure 2). 
Figure 2. Prevalence (%) of different types of diabetes; data is from the ANDIS project, 
adapted and modified from the ANDIS website (4) 
 
Classification of LADA 
There is currently no uniform definition of LADA. Three clinical criteria are commonly used: 
1) autoantibody positivity, predominantly autoantibodies to glutamic acid decarboxylase 
(GADA), which differentiates LADA from type 2 diabetes, 2) adult onset (usually 35 years or 
72.6% 
6% 
4.8% 
Classical type 2 diabetes
Type 2 diabetes with relative insulin deficiency
Type 2 diabetes in youth
Type 1 diabetes in adults
Type 1 diabetes with relative insulin deficiency
Type 1 diabetes with absolute insulin deficiency
LADA
Secondary diabetes
Unclassified
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older), and 3) insulin independency 6-12 months after diagnosis, to distinguish LADA from 
type 1 diabetes (27; 90; 91).  
All of these criteria have been debated: The age criterion is based on an arbitrary limit, and 
one could ask; what is the significant difference between a patient with autoimmunity who is 
diagnosed at age 34 and another who is diagnosed at 36 years of age? (70; 92; 93). GADA 
has been questioned because there may be other markers of autoimmunity like autoantibodies 
directed towards insulin (IAA), and autoantibodies to islet cells (ICA). One argument against 
this is that it has been shown that GADA is the antibody with the highest penetration, being 
present in 70-80% of LADA patients (94). Finally, the commonly used insulin criterion is a 
subjective method which depends on the assessment of the individual physician (91). C-
peptide is suggested as an alternative, more objective indicator remaining β-cell function 
(95). Each of these criteria is based on arbitrary cutoffs which makes the diagnosis of 
LADA variable in different studies and hampers comparisons across studies.  
Genetic risk factors 
Data from a limited number of studies indicate that the risk of LADA is increased four-fold in 
individuals with diabetes in the family (82). Knowledge on the genetic predisposition of 
LADA is not as extensive as for type 1 and type 2 diabetes, but an admixture of genetic 
characteristics of both type 1 and type 2 diabetes has been suggested (20). Like type 1 
diabetes, HLA-risk genotype, especially HLA-DQB1*02/*0302 allele was positively 
associated with increased risk of LADA (3; 19; 90; 96; 97). The protective DQB1*0602 allele 
is higher in LADA than type 1 diabetes (19; 90; 96). Within LADA, the associations of both 
HLA-risk and protective seem to depend on GADA concentrations; LADA patients with high 
GADA have higher frequency of these risk variants than LADA patients with low GADA (3; 
19; 90). Similarly, PTPN22 was associated with LADA overall or with LADA with high 
GADA (96; 98). The CTLA4 gene is also associated with higher risk of LADA (99). 
Regarding INS gene data is inconsistent; some show similar association for LADA as type 1 
diabetes (96), whereas others show no association (90).   
There are also genetic similarities between LADA and type 2 diabetes. A variant of TCF7L2, 
as the strongest gene for type 2 diabetes, has been associated with LADA in several studies 
(96; 100; 101). The obesity-associated variant of FTO was associated with LADA, 
particularly LADA with low GADA (90). No association was found between SLC30A8 and 
PPARG and LADA (90). 
This genetic similarity with both classical type 1 and type 2 diabetes supports the view that 
LADA is a hybrid form of diabetes (20; 90; 96). Moreover, this data suggests that LADA is 
heterogeneous disease which is mostly related to the variability in GADA levels (20); LADA 
patients with high GADA titers are found to be genetically more similar to type 1 diabetes, 
whereas LADA with low GADA levels are more type 2-like (20).  
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Environmental risk factors 
In the pathogenesis of LADA both autoimmunity and insulin resistance seem to be involved 
(74). It is hence plausible that risk factors for LADA could be the same as those for type 2 
diabetes and be mediated primarily by insulin resistance, or they could be the same as for 
type 1 diabetes, triggering autoimmunity, or they could be a mix. Knowledge on potential 
risk factors for LADA is at present very limited. 
One reason for the lack of studies on risk factors may be that in most observational studies 
the indicators of autoimmunity which is needed to distinguish LADA from type 2 diabetes 
patients have not been measured. Exceptions are the Norwegian HUNT-study (102), a 
longitudinal study conducted in the middle of Norway, and the Swedish ESTRID-study; a 
population-based case-control study which recruits patients primarily through the ANDIS-
registry in Scania, a county in the South of Sweden (4). Data from these studies indicate that 
risk factors for LADA to some extent are similar to those of type 2 diabetes and include 
overweight, physical inactivity (81), low birth weight (80), low psychosocial well-being and 
sleep disturbances (83) In contrast, high education (86), and coffee consumption (85) were 
associated with an increased risk for LADA, whereas smoking was associated with a reduced 
risk (84), in line with previous findings in type 1 diabetes (103-105). These findings support 
the notion that LADA has shared characteristics with both type 1 and type 2 diabetes and that 
environmental risk factors may be related to autoimmunity as well as insulin resistance. 
Studies are however few and confirmation and extension of these findings and exploration of 
additional lifestyle factors are clearly warranted.   
2.3 ALCOHOL CONSUMPTION 
Moderate alcohol intake is associated with a 30-40% reduced risk of type 2 diabetes (106-
109). The beneficial effect of alcohol could be attributed to improvement of insulin 
sensitivity (110-113), beneficial postprandial effects (alcohol reduces the peak of blood 
glucose levels after meals (114)), anti-inflammatory effects (115; 116), and elevated 
circulating adiponectin, which plays an important role in regulating metabolism of glucose 
and lipids (117-120).  
Drinking pattern is also important; frequent drinking is associated with reduced risk of type 2 
diabetes compared to episodic or binge drinking (108; 121). The ethanol itself rather than 
particular components of different alcoholic drinks appears to be carrying beneficial health 
effects, but some studies have shown that wine is more beneficial than other alcohol 
containing drinks like beer and liquor (109; 121). Possibly, it is due to presence of other 
compounds rather than ethanol, such as polyphenols and hydroxylated Stilbenes, which play 
an anti-oxidative or anti-inflammatory role in the body (122; 123).   
Alcohol consumption has previously not been studied in relation to LADA. There are 
however, some studies indicating that moderate alcohol intake is associated with a reduced 
risk of other autoimmune disorders such as rheumatoid arthritis (124; 125), and Graves’ 
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hyperthyroidism (126). A possible underlying mechanism could be that alcohol reduces some 
markers of inflammation and regulates the immune system (115; 116; 127-129).  
2.4 SMOKING 
Smoking, particularly heavy smoking, is a well-known risk factor for type 2 diabetes (41; 84; 
130-137); A systematic review showed that current smoking is associated with a 44% 
increased risk of type 2 diabetes (41) and the risk increases in a dose-dependent manner (84; 
133; 138). Cigarette contains over 4000 chemical substances and more than 200 of them are 
believed to be toxic, including nicotine, tar, and carbon monoxide. Studies have shown that 
smoking is more harmful in individuals with high BMI (138), suggesting that overweight 
may modify the effect of smoking on type 2 diabetes. The association between smoking and 
type 2 diabetes has primarily been attributed to smoking/nicotine-induced insulin resistance 
(139; 140), but increased systematic inflammation (141), greater accumulation of abdominal 
adipose tissues (142), and adverse effects on pancreatic tissue and β-cell function (143) may 
also contribute to the excess risk.  
A small study based on HUNT (follow-up between 1984 and 1997) indicated that smoking 
may reduce the risk of LADA (84). It was based on only 35 smoking LADA patients and 
replication of these findings is thus needed. These findings are in line with previous 
observations in type 1 diabetes, suggesting a reduced risk in the offspring of smoking parents 
(103-105). A proposed mechanism behind a beneficial effect could be the anti-inflammatory 
and immune-modulating effect of smoking/exposure to nicotine (144; 145). This potential 
biologic mechanism is controversial (144-147).  
2.5 MOIST SNUFF (SNUS) USE 
Swedish moist snuff (Snus) is a smokeless tobacco product that contains ground tobacco, salt, 
water, aromatic and humidifying substances. The use of moist snuff is popular in Sweden, 
where 20% of men and 4% of women use it on a daily basis (148). Moist snuff is steadily on 
the rise in Norway and the United States (149), where the sale of moist snuff is permitted. 
The influence of smoking on type 2 diabetes has been attributed, at least in part, to nicotine 
(139; 140). It has been suggested that moist snuff, with even higher nicotine content and 
comparable nicotine bioavailability as cigarettes (150), increases the risk of type 2 diabetes 
(151; 152), but results from the small number of studies are inconsistent [6]. One reason for 
conflicting results may be insufficient adjustment for smoking, which is common among 
moist snuff users. Larger studies will allow for restriction of the analyses to never smokers, 
which is an efficient way of handling this potential confounding.  
If smoking reduces the risk of LADA (153) by way of an inhibitory effect of nicotine on 
autoimmunity/inflammation (144), one could hypothesize that moist snuff, with its higher 
nicotine content, may have an even stronger beneficial effect. Whether this is the case, 
remains to be explored. 
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3 AIM 
3.1 OVERALL AIM 
To study the influence of alcohol and tobacco use on the risk of LADA, and to address these 
exposures in relation to type 2 diabetes in order to compare the etiology of LADA and type 2 
diabetes.  
3.2 SPECIFIC AIMS 
Study I and II: To study weather alcohol consumption is associated with the risk of LADA 
and whether the association is dependent on degree of autoimmunity as assessed by GADA 
level. 
Study III and IV: To assess the association between smoking and the risk of LADA.  
Study V: To study the association between use of moist snuff and the risk of LADA and type 
2 diabetes. 
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4 MATERIAL AND METHODS  
4.1 HUNT STUDY (PAPERS I, III, AND V) 
The Nord-Trøndelag County is located in the middle of Norway with a total of ~127,500 
inhabitants (figure 3). During 1984-2008, all inhabitants aged ≥20 year old living in the 
county were invited to the HUNT Study, where the health of the population was extensively 
investigated in three separate surveys (HUNT1, HUNT2, and HUNT3). 
Figure 3. Nord-Trøndelag County (154). 
 
 
The first survey (HUNT 1) was undertaken in the period of 1984-1986 and the participation 
rate was 90.3% (n=76,885). HUNT2 was conducted from 1995 to 1997 (102; 155). The 
participation rate in this follow-up study was 71.3% (n=66,140) and among those still alive, 
78% (n=46,559) of participants in HUNT1 re-attended in HUNT2. The third survey 
(HUNT3) was started in 2006 and completed in 2008, with similar design as the two previous 
ones, including 50,839 participants (attendance rate=54%), and of those still alive, about 70% 
(n=37,004) of participants in HUNT2 re-attend in HUNT3 (86; 156-158). An overview of the 
HUNT Study is given in figure 4.  
Participants filled out a self-administrated questionnaire, including detailed information on 
health, lifestyle, and demographic factors and participated in a clinical examination including 
anthropometric measurements and blood sampling. Diabetes was identified by self-reporting; 
a high accuracy is reported between this self-reported information and medical records (96% 
of the diabetes cases were verified) (159). Individuals who reported having diabetes in 
HUNT2 or HUNT3 were invited to a separate diabetes investigation, including blood 
sampling and detailed questions on treatment and age at onset (102; 155; 157; 160; 161).  
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 Figure 4. A chart presentation for the HUNT studies (The Nord-Trøndelag Health Survey); 
1984–2008. Adapted from Krokstad et al (158) 
 
4.1.1 Study population 
Paper I, Alcohol and LADA/type 2 diabetes: For the analysis of frequency of alcohol intake 
we used data from all three HUNT surveys (HUNT1-3) and formed a cohort consisting of 
individuals who were free of diabetes at baseline (HUNT1 or HUNT2; depending on when 
the participant entered the study) who also participated in at least one follow-up survey 
(HUNT2 or HUNT3). Eligible for the analyses were 90,296 individuals (964,890 person-
years) and among those, 1841 incident cases of type 2 diabetes, and 140 cases of LADA were 
identified during the 22 year follow-up (1984-2008). Information on amount of alcohol 
consumed was available only at HUNT2 why we formed second cohort including 42,033 
participants (444,238 person-years) who were free of diabetes at HUNT2 (baseline) and 
among those, we identified 940 incident case of type 2 diabetes and 46 cases of LADA 
during 11-years of follow-up (1995-2008).    
Paper III, Smoking and LADA/type 2 diabetes: Information from all three HUNT surveys 
(HUNT1-3) was used to form a cohort of individuals who could be followed prospectively 
for incidence of diabetes during 11-22 years. Eligible were individuals who were free of 
diabetes at baseline (HUNT1 or HUNT2; depending on when the participant entered the 
study) with complete baseline information on smoking; 1860 incident cases of type 2 diabetes 
and 140 cases of LADA were identified in 968,641 person-years of follow-up.  
  15 
Paper V, Moist snuff use and type 2 diabetes: Information on moist snuff use was only 
available for the latest HUNT investigation (HUNT3), conducted 2006-2008. Hence, moist 
snuff use was analyzed cross-sectionally in relation to diabetes including 829 prevalent cases 
of type 2 diabetes and 21,473 individuals without diabetes. LADA patients were not included 
in the analysis as the numbers were too small (n=10) to allow for meaningful analyses. The 
analyses were restricted to men due to the low prevalence of moist snuff use in women 
(~4%).  
4.1.2 Biochemical analysis 
All individuals with self-reported diabetes at HUNT2 and HUNT3 were invited to a second 
investigation for fasting blood sampling. Blood samples were analyzed for GADA, C-
peptide, and glucose. For the patients who did not attend the supplementary examination, 
serum samples were available at the HUNT Biobank (86; 90). Among all individuals with 
diabetes, only 4.5% had missing data on GADA.  
The analysis of GADA was performed at Aker University Hospital, Oslo, Norway, by a 
previously validated method (102). GADA was reported as an antibody index value in 
relation to standard serum (162). A value of ≥0.08 was considered positive. At this cutoff, the 
sensitivity and specificity was 0.64 and 1.00, respectively, according to results obtained in 
through the Diabetes Antibody Standardization Program (163). GADA values were also 
transformed to World Health Organization units, it was calculated as 0.08=43 WHO units/mL 
(164). C-peptide was measured via radioimmunoassay (Diagnostic System Laboratories, 
Webster, TX) (102; 157). Fasting serum levels of glucose were measured by Hemocue at the 
central laboratory of Levanger Hospital (Levanger, Norway) (13). Homeostasis model 
assessment for insulin resistance (HOMA2-IR) and β-cell function (HOMA2-% B) were 
calculated using HOMA2 calculator(165). 
4.1.3 Classification of diabetes 
GADA and age at onset were used to classify the diabetes patients; Patients with age at onset 
≥35 years were classified as having type 2 diabetes if they were GADA negative (<0.08) and 
as having autoimmune diabetes in adults if they were GADA positive (≥0.08). As a further 
criterion, we used information on insulin treatment to separate LADA from classical type 1 
diabetes. Individuals were classified as having LADA if they were GADA positive and did 
not use insulin during the first year after diagnosis and as having classical type 1 diabetes if 
insulin treatment was started less than one year after onset. Unfortunately information on 
treatment was only available for 79.5% of patients, and thus the distinction between LADA 
and type 1 diabetes could not be made for all autoimmune patients with adult onset.  
Since the majority of autoimmune diabetes patients in HUNT had LADA (85.7% of those 
with information on treatment belonged to this group), and because of the limited number of 
cases, we chose to combine LADA and type 1 diabetes in the main analysis of paper I and III. 
Throughout the thesis, for practical reasons and in order to avoid introducing a new term 
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(AIDA-autoimmune diabetes in adults), I will refer to this patient group as LADA. 
Importantly, sensitivity analyses were run with LADA as outcome in all papers based on 
HUNT data and the results were similar to those based on the whole group of autoimmune 
patients with adult onset (paper I and III). 
4.1.4 Questionnaire data 
Information on health and lifestyle factors, including tobacco use and alcohol consumption 
was collected by questionnaire. The questionnaires used in the HUNT surveys can be found 
at http://www.ntnu.edu/hunt/data/que.   
4.1.4.1 Alcohol consumption (Paper I) 
In the HUNT1 questionnaire information on frequency of alcohol intake was available, 
through a question on how often, on average over the last 14 days, participants consumed 
alcoholic drinks; and the five response options ranged from: non-consumers  to >10 times. 
No information on the amount consumed was collected. 
The HUNT2 questionnaires contained detailed questions about alcohol consumption. The 
following question were used to determine the quantity and also type of consumed alcoholic 
drinks: “How many glasses of beer, wine or spirits do you usually drink in the course of two 
weeks?”. To calculate the total average grams of alcohol consumption per day we multiplied 
the reported amount by the estimated alcohol content for each alcoholic beverage, and then 
we summed them up to get the total daily alcohol consumption. The estimated alcohol 
contents were 16 gram for one can/bottle/glass of beer, 12 gram for one glass of wine and 12 
gram for one standard drink of spirit (166). Participants were categorized into different 
consumption groups according to this information, varying from 0.01 to ≥15 gram/day 
(reference group: 0.01-5 gram/day). For LADA analysis due to few numbers in each 
category, alcohol consumption was reclassified based on quartiles. The frequency of alcohol 
consumption was also derived from this question: “How many times a month do you usually 
drink alcohol?”. 
4.1.4.2 Smoking (Paper III) 
Detailed information on smoking history was collected in both HUNT1 and HUNT2. Based 
on information on smoking habits participants were categorized into three groups: never 
smokers, former smokers and current smokers. Current and former smokers were asked; 
“How old were you when you started smoking?”, “How many years in total have you smoked 
daily?”, and “How many cigarettes do you or did you usually smoke daily?”. The intensity of 
smoking among current and former smokers was assessed in two categories; light smokers 
(<20 cigarettes/day) and heavy smokers (≥20 cigarettes/day). One pack year corresponds to 
smoking 20 cigarettes per day for a year. Pack-year was assessed in three categories; <6, 6-12 
and ≥13. 
  17 
4.1.4.3 Moist snuff use (Paper V)  
Information on moist snuff use was available from HUNT3. Participants were asked whether 
they had ever used moist snuff. Individuals were considered as current users if they used 
moist snuff on a daily basis or occasionally. Ever moist snuff users were asked about the 
number of boxes consumed per month, and they were classified into two groups (<3 and ≥3 
boxes/week). 
4.1.4.4 Confounding factors 
In HUNT height and weight was measured at the clinical investigation. Body mass index 
(BMI) was calculated as weight in kilograms divided by the square of height in meters. 
Family history of diabetes was considered positive if any first-degree relative had any type of 
diabetes (yes/no). Educational level categorized into three groups: primary school, upper 
secondary school or university. Smoking was analyzed continuous (pack-year; in moist snuff 
analysis) or categorized as: never, former, and current smokers. Questions about leisure time 
physical activity was used to categorize participants as having high activity, moderate activity 
or as being inactive; categorization details are described elsewhere (167).  
4.2 ESTRID STUDY (PAPERS II, IV, AND V) 
ESTRID (Epidemiological Study of Risk factors for LADA and type 2 Diabetes; 
http://ki.se/imm/estrid) is an ongoing population-based case-control study conducted in 
Sweden.  Patients are recruited primarily through the before mentioned ANDIS-study 
(http://andis.ludc.med.lu.se). 
ANDIS is an ongoing large scale study attempting to classify 
and monitor all new diabetes cases in Scania, a county in 
southern part of Sweden with ~1,300,000 inhabitants (figure 
5). The aim of ANDIS is to describe the diabetes spectrum 
on the basis of clinical features and genetic factors.  
To ESTRID we invite all incident cases of LADA identified 
in ANDIS since 2010, together with a random sample of type 
2 diabetes cases (4 per LADA case). Controls ≥35 years old 
without diabetes are randomly selected from the population 
registry and matched to the case by date of participation and 
residential area (incidence density sampling (168)). Six controls are selected per LADA case, 
corresponding to 1 control per case of diabetes (LADA or type 2). In 2012, a sister-study to 
ANDIS was launched in Uppsala County (~350 000 inhabitants), the ANDIU-study (All New 
Diabetic in Uppsala; http://www.andiu.se/). Since 2012, ESTRID recruits cases and controls 
also in Uppsala. To date (February 2016), 414 LADA and 1380 type 2 diabetes cases and 
1793 controls have been included in ESTRID with a participation rate of 81% among cases 
and 66% among controls. Of the participants, 97% come from Scania and 3% from Uppsala. 
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Figure 5. A chart presentation of the ESTRID Study, 2010–2016 
 
4.2.1 Study population 
ESTRID is an ongoing study and the data collection is continuing. The ESTRID dataset has 
been updated annually. 
Paper II: For this paper we used information from the dataset updated in August 2013; and  
included 250 cases of LADA, 764 cases of type 2 diabetes, and 1012 controls with complete 
information on alcohol consumption and covariates. 
The newest update was done in July 2015 and analyses of papers IV and V were based on 
that dataset. 
Paper IV: It included cases and controls with available information on smoking and other 
covariates of interest, consisting of 377 LADA cases, 1188 type 2 diabetes cases, and 1472 
controls.  
Paper V: It was restricted to men, due to low prevalence of moist snuff use among women 
(~4%). All men with complete data on moist snuff use and covariates of interest were 
included in paper V, comprising 200 LADA cases, 724 type 2 diabetes cases, and 699 
controls. 
4.2.2 Biochemical analysis 
The clinical measurements were conducted only in diabetes patients. All blood samples were 
collected from patients at time of diagnosis and analyzed at Lund university laboratory, 
Malmö, Sweden. GADA was analyzed with ELISA assay (Enzyme-linked immunosorbent 
assay; ELISA, RSR Ltd.). GADA was regarded as positive if the serum antibody level >10 
IU/mL. ELISA assay showed 84% sensitivity and 98% specificity at a cutoff of 10.7 IU/mL 
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(14). C-peptide concentrations were determined by using the IMMULITE 2000 (Siemens 
Healthcare Diagnostics Product Ltd., Llanberis, UK) or by Cobas e 601 analyzer (Roche 
Diagnostics, Mannheim, Germany) (169). Fasting plasma glucose and C-peptide were used to 
calculate Homeostasis model assessment (HOMA)-IR to estimate insulin resistance and 
HOMA-%B to assess β-cell function (165).  
4.2.3 Classification of diabetes 
Patients were diagnosed in the primary health care of Scania and Uppsala counties. Based on 
age at onset and GADA and C-peptide measurements, cases with age-at-onset ≥35 years were 
classified as LADA if they were GADA positive (≥10 IU/mL) with C-peptide ≥0.2 nmol/l 
(IMMULITE)/or ≥0.3 nmol/l (Cobas e 601). C-peptide was used here to indicate remaining 
β-cell function and separate LADA from type 1 diabetes, as previously suggested (14; 170).  
Patients were classified as having type 2 diabetes if they had onset ≥35 years, were GADA 
negative (<10) and had C-peptide >0.6 nmol/l (IMMULITE) /or ≥0.72 with Cobas e 601. 
Cases of LADA were further stratified into subgroups by median GADA levels; LADA with 
high GADA, and LADA with low GADA (Papers II and IV).  
4.2.4 Questionnaire data 
ESTRID participants filled out questionnaires containing information on health, 
anthropometrics, and lifestyle factors, including tobacco use and alcohol consumption. The 
questionnaires used in the ESTRID are available at http://ki.se/imm/estrid. Patients received 
questionnaires in proximity to diagnosis with careful instructions to report their lifestyle as it 
was prior to diagnosis. 
4.2.4.1 Alcohol consumption (Paper II) 
The ESTRID questionnaires contained a previously validated food frequency questionnaire 
for alcohol intake (171). Participants were asked how often they consumed alcoholic drinks. 
Among current drinkers, data on frequency of consumption for different alcoholic drinks 
were collected. Information on the amount of each alcoholic beverage consumed on each 
occasion was also collected with an open ended question (given in centiliters [cl] for each 
unit of can, bottle, or glass). Total average intake of alcohol in grams per day was computed 
by combining information of frequency and amount of drinking. The content of alcohol per cl 
alcoholic beverage was estimated as follows: 0.25 g for light beer, 0.40 g for strong beer, 0.40 
g for cider, 0.85 g for wine, 1.5 g for liquor, and 3 g for hard liquor. The variable was 
analyzed both categorized and continuous. Frequency of alcohol consumption was also 
classified into five groups ranging from ≤1time/month (as reference group), to ≥1 time/day.  
4.2.4.2 Smoking (Paper IV) 
There were detailed questions on lifetime smoking habits, including smoking status (current, 
former, and never), time-points for start and stop of smoking, and number of cigarettes 
smoked per day. Participants were categorized by smoking intensity into light and heavy 
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smokers (<20 or ≥20 cigarettes/day). Cumulative dose of smoking (pack-year) was regarded 
as equivalent to 20 cigarettes smoked daily for one year, and assessed in three categories 
(never, 0–15, and ≥15). The exposure to smoking was assessed for the period of time before 
index year (for cases the year of diagnosis, and for controls, participation year). 
4.2.4.3 Moist snuff use (Paper V)  
Lifetime history of moist snuff use was assessed, including status of snuffing (current, 
former, never), number of boxes consumed weekly, and time-points for start and stop of 
snuffing. Moist snuff use was categorized according to intensity of consumption (<5, and ≥5 
boxes/week), and cumulative dose of snuffing (<10, and ≥10 box-year). One box-year was 
defined as consumption of one box of moist snuff per day for one year. An index year was 
defined as year of diagnosis for cases and year of participation for controls. The exposure to 
moist snuff use was assessed prior to the index year.  
4.2.4.4 Confounding factors 
Body mass index (BMI) was calculated as weight (kg)/height (m)
2
. Any family history of 
diabetes was considered as positive (yes/no). Educational level classified into: primary 
school, upper secondary school or university. Participants were categorized according to their 
smoking habits into: never, former, and current smokers; pack-year of smoking (continuous) 
was also available. Alcohol consumption was categorized as (0.1–4.9 g/day, 5–14.9 g/day, 
and ≥15 g/day). Educational level was classified into three categories; primary, secondary, 
and university. Physical activity categorized as physically active, or inactive. 
4.3 STATISTICAL ANALYSIS 
HUNT Study: 
For the prospective studies (Papers I and III), hazards ratios (HR) and confidence intervals 
(CI) were estimated by Cox proportional hazards regression models. We used age as 
underlying timescale in the cox models. Person-years of follow-up were calculated from the 
age that the participant entered the study (HUNT1 or HUNT2) until age at onset of diabetes, 
death or age at end of the follow-up period at HUNT2 (1997) or HUNT3 (2008), whichever 
came first.  
In the cross-sectional analysis of paper V we used logistic regression to estimate prevalence 
odds ratios (POR) for type 2 diabetes in relation to moist snuff use. 
ESTRID Study: 
In the case-control analyses of papers II, IV, and V based on the ESTRID study, we used 
logistic regression to estimate odds ratios (OR) and CIs according to case-control 
methodology. The incidence density sampling scheme of the controls (matching for date of 
participation and residential area) allowed us to interpret ORs as incidence rate ratios (168). 
We performed conditional logistic regression, matched for residential area and time of 
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participation in papers IV and V. For paper II both conditional and unconditional analyses 
were conducted. The ORs of unmatched analyses were in close agreement with those from 
matched analyses; we preferred to present the results of unconditional analyses as they made 
more efficient use of our limited data.  
Restricted cubic spline regression was used in paper II to model potential dose-response 
relationship between total grams of alcohol consumption per day and risk of LADA and type 
2 diabetes. This model is a common tool for testing non-linearity function of  a continuous 
covariate relaxing the assumption of linearity, it also has the advantage compared to using 
categorical data that we do not lose information (172). 
Linear least squares regression was used to assess the association between alcohol 
consumption (papers I and II), smoking (paper IV), and HOMA indices. The association with 
GADA was assessed using the Tobit regression model to account for the fact that GADA 
(outcome variable) was truncated at 250 (173). 
All analyses were carried out using the Statistical Analysis System (SAS 9.2, 9.3, and 9.4; 
SAS Institute Inc, Cary, NC). We used Stata for restricted cubic spline regression (Stata 
version SE13.0, College Station, TX, USA).  
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5 RESULTS 
5.1 POPULATION CHARACTERISTICS; COMPARISON OF HUNT AND 
ESTRID  
The HUNT and ESTRID participants were similar with regard to many characteristics (table 
1), however, compared to ESTRID participants, those in HUNT were slightly leaner, and had 
lower prevalence of heavy smoking and family history of diabetes, and higher proportion of 
low education and physical inactivity.  
LADA patients at HUNT compared to those in ESTRID were heavier, and had higher 
prevalence of family history of diabetes, and lower proportion of ever/or heavy smoking. 
They had lower levels of HOMA-IR and higher HOMA-β. The median levels of GADA were 
higher in the LADA patients of ESTRID (177 WHO unites/ml) compared to those of HUNT 
(140 WHO unites/ml).   
5.2 PAPER I, ALCOHOL AND LADA/TYPE 2 DIABETES IN HUNT 
Results based on 22 years follow-up suggested that frequent alcohol intake was associated 
with a reduced risk of LADA (HR for 1-4 times over the last 14 days; 0.70, 95% CI; 0.45-
1.08) and type 2 diabetes (HR; 0.68, 95% CI; 0.49–0.93) (table 2). Results of 11 years 
follow-up, with information on amount of alcohol consumed indicated a 60% reduced risk of 
LADA (HR, 0.38, 95 % CI=0.15-0.98) in those consuming 2-7 gram/day. Similar findings 
were seen for type 2 diabetes (HR for 10-15 gram alcohol /day; 0.48, 95% CI; 0.28-0.77).  
5.3 PAPER II, ALCOHOL AND LADA/TYPE 2 DIABETES IN ESTRID 
The findings suggested that alcohol consumption was dose-dependently (tested with 
restricted cubic spline models) and inversely associated with the risk of LADA (OR for every 
5-g increment; 0.94; 95% CI; 0.89-0.99). The lowest risk was seen in those consuming 5–15 
g/day (OR; 0.56, 95% CI; 0.41–0.77) (table 3). Stratification of LADA cases by median 
GADA (≤median; 152 IU/ml) revealed that the risk reduction was restricted to more type 2-
like LADA (LADA with low GADA) (OR for every 5-g increment 0.85; 95% CI; 0.76-0.94) 
whereas no reduced risk was seen for more autoimmune, high-GADA LADA. In line with 
this, every 5-g increment of daily alcohol intake was associated with 10% reduction in 
HOMA-IR (p=0.0418) in LADA patients, and an 8% reduction in patients with type 2 
diabetes (p=0.0345). Wine consumption (OR 0.95 per 5-g wine, 95% CI; 0.89-1.02 [LADA]; 
OR; 0.94, 95% CI; 0.90–0.99 [type 2 diabetes]) rather than beer and liquor intake was 
inversely related to diabetes risk.  
We reanalyzed the HUNT data stratified by median GADA levels (paper II). The results 
indicated that the possible benefit of alcohol intake on LADA was restricted to LADA 
patients with low GADA (HR; 0.54, 95% CI; 0.29–0.99) but not LADA with high GADA 
(0.93, 95% CI 0.48–1.80). Of note, the numbers of cases were very low in these analyses. 
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Table1. Characteristics of participants in in HUNT (1984-2008) and in ESTRID (2010-2015). 
 HUNT study 
a
  
 
ESTRID study 
a
 
 Individuals 
without 
diabetes  
LADA 
β
 Type 2 diabetes  Controls LADA Type 2 diabetes 
No. of individuals (N)  114549 164 2244  1495 378 1204 
Age at onset of diabetes, mean, y (SD) - 59 (11) 61 (11)  - 59 (12) 63 (10) 
Men, N (%) 54205 (47) 80 (49) 1170 (52)  705 (47) 201 (53) 726 (60) 
Low education, N (%) 45086 (51) 81 (59) 1140 (61)  361 (24) 113 (30) 450 (37) 
BMI, mean, kg/m2 (SD) 25.5 (3.8) 29.1 (5.0) 29.8 (4.5)  25.9 (4.1) 28·1 (5.3) 31.1 (5.4) 
Obese (BMI≥30), N (%) 1152 (12) 59 (42) 852 (43)  218 (15) 118 (31) 613 (51) 
Physical inactive, N (%) 28650 (33) 58 (42) 688 (38)  221 (15) 63 (17) 271 (23) 
Alcohol abstainers, N (%) 10503 (12) 20 (14) 262 (14)  142 (10) 43 (11) 165 (14) 
With Family History of Diabetes, N (%) 37449 (33) 90 (55) 1436 (64)  354 (24) 167 (44) 595 (49) 
Ever smokers, N (%) 48084 (54) 65 (46) 1027 (55)  767 (51) 207 (55) 756 (63) 
Heavy smokers, N (%) 6203 (7) 7 (5) 213 (12)  168 (12) 67 (18) 238 (21) 
C-peptide, mean (SD), nmol/l - 0.66 (0.56) 0.93 (0.53)  - 0.81 (0.53) 1.33 (0.58) 
Fasting plasma glucose, mean (SD), mmol/L - 8.8 (3.2) 8.3 (2.4)  - 15.5 (8.3) 11.3 (6.2) 
HOMA_IR, mean (SD) - 2.3 (1.4) 2.5 (1.3)  - 5.2 (13.0) 5.8 (13.4) 
HOMA_B, mean (SD) - 70 (47) 71 (41)  - 45 (35) 69 (36) 
GADA, median (interquartile range), WHO unites/ml - 140 (59-572) -  - 177 (25-250) - 
a
 The total numbers in ESTRID and HUNT studies. The numbers might differ with the ones presented in the studies due to missing values of covariates included in the models.  
β 
Adults with autoimmune diabetes, including LADA (85.7%) and type 1 diabetes patients in adult
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Table 2. HRs of LADA and type 2 diabetes in relation to frequency of alcohol consumption, 
HUNT Study, 1984-2008 
  LADA   Type 2 diabetes 
 Person-year No. cases HR 
(95% CI) 
α
 
 No. cases  HR 
(95% CI)
 α
 
Frequency of alcohol intake during the last 14 days    
   Abstainers 104,870 20 0.77 (0.42-1.40)  262 0.94 (0.79-1.10) 
   < 1 time  358,980 70 Reference  765 Reference 
   1-4 times 456,271 43 0.70 (0.45-1.08)  736 0.99 (0.88-1.11) 
   5-10 times 27,782 7
 β
 0.72 (0.28-1.83)  40 0.71 (0.51-0.99) 
   >10 times  16,987 - -  38 0.88 (0.61-1.26) 
α
 HRs are adjusted for age, sex, BMI, smoking, family history of diabetes, education, and physical activity 
β
 Two high frequent alcohol intake categories were combined because of small numbers. 
Table 3. ORs of LADA and type 2 diabetes in relation to alcohol consumption, ESTRID 
Study, 2010-2013 
 Type 2 diabetes LADA Low GADA 
(≤median;152 IU/mL) 
LADA High GADA 
(>median;152 IU/mL) 
 Cases/ 
controls 
OR 
(95% CI) 
α
 
Cases/ 
controls 
OR 
(95% CI) 
α
 
Cases/ 
controls 
OR 
(95% CI)
 α
 
Alcohol intake (g/day)      
Non-drinkers 
β
 106/94 1.34 (0.89-2.00) 16/94 0.97 (0.51–1.84) 9/94 0.92 (0.42-2.01) 
 0·01-4.9  305/343 Reference 54/343 Reference 39/343 Reference 
 5-14·9  177/340 0.56 (0.41-0.77) 36/340 0.60 (0.37–0.97) 38/340 0.95 (0.58-1.56) 
 15-24·9  83/130 0.59 (0.39-0.87) 11/130 0.42 (0.21–0.86) 23/130 1.33 (0.74-2.38) 
 ≥25 93/105 0.58 (0.38-0.88) 6/105 0.23 (0.10–0.57) 14/105 1.01 (0.50-2.02) 
Alcohol  (per 5g/day) 0.95 (0.92-0.99)  0.85 (0.76-0.94)  1.00 (0.94-1.06) 
α
 Adjusted for age, sex, BMI, family history of diabetes, smoking, and education 
β
 Non-drinkers: including abstainers and former drinkers 
γ
 Analyses were run only in alcohol drinkers; additional adjustment for total alcohol intake 
5.4 PAPER III, SMOKING AND LADA/TYPE 2 DIABETES IN HUNT 
Current smoking was associated with a 48% reduced risk of LADA (HR; 0.52, 95% CI; 
0.30–0.89), and heavy smoking with 58% reduced risk (HR; 0.42, 95% CI; .18–0.98) (figure 
6). Compared to never smoking, heavy smoking was associated with lower levels of GADA 
(0.009 vs.0.056; p=0.001). In contrast, heavy smoking was associated with an increased risk 
of type 2 diabetes (HR; 1.32, 95% CI=1.11-1.56), which was most evident in overweight men 
(HR; 1.70, 95% CI=1.38-2.10).  
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Figure 6. HR of LADA and type 2 diabetes in relation to smoking, results from HUNT, 1984-
2008.  
 
5.5 PAPER IV, SMOKING AND LADA/TYPE 2 DIABETES IN ESTRID 
In this case-control study, we did not find any indication of reduced risk of LADA in smokers 
(OR in current smokers; 1.26, 95% CI; 0.93-1.72). These findings were consistent when 
analyses were stratified by family history of diabetes (yes, no), BMI (<25, ≥25 kg/m2), age 
(<55, ≥55 year), and median level of GADA (<178, ≥178 IU/mL). Instead, heavy smoking 
(≥15 pack-year) was associated with an increased risk of LADA (OR; 1.37, 95% CI; 1.02-
1.84) (figure 7). Comparing heavy and never smoking LADA patients indicated higher mean 
levels of HOMA-IR (9.89 vs. 4.38, p=0.0479) and HOMA-B (55.7 vs. 42.5, p=0.0204) in 
smokers. Also, heavy smokers had lower median levels of GADA (75 vs. 250, p=0.0445), 
compared with never smokers. Smokers also had an increased risk of type 2 diabetes (OR for 
≥20 cigarettes/day; 1.73, 95% CI; 1.00-2.99) (figure 7).  
Figure 7: OR of LADA and type 2 diabetes in relation to smoking, results from ESTRID, 
2010-2015. 
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5.6 PAPER V, SNUFFING AND LADA/TYPE 2 DIABETES IN ESTRID AND 
HUNT 
In ESTRID there was no indication of an excess risk of LADA in snuff users; in never 
smokers, OR was estimated at 1.01 (95% CI; 0.45-2.29) for ≥10 box-years (table 4). For type 
2 diabetes, results were similar, high snuff consumption was associated an OR of 1.01 (95% 
CI; 0.42-2.41) in ESTRID and a POR of 0.89 (95% CI; 0.21-3.78) in HUNT. 
Combining exposure from moist snuff and cigarettes indicated that exclusive smokers (ever) 
have an increased risk of type 2 diabetes (OR; 1.59, 95% CI; 1.16-2.18) which was even 
more pronounced in heavy smokers (OR; 2.20, 95% CI; 1.40-3.45). No increased risk was 
seen in exclusive moist snuff users, nor in subjects who combine snuffing and smoking. 
Similar findings were seen in HUNT (table 5).  
Table 4. OR of LADA and type 2 diabetes in relation to moist snuff use in men, ESTRID 
(2010-2015), and HUNT3 (2006-2008)  
 Ever smokers Never smokers 
 Cases/ 
subjects 
without 
diabetes  
OR 
(95% CI) 
α β
 
Cases/ 
subjects 
without 
diabetes 
OR 
(95% CI) 
α β
 
ESTRID     
Type 2 diabetes     
  Never 310/223 reference 205/254 reference 
  Current  92/92 0.91 (0.39-1.01) 27/36 1.17 (0.58-2.37) 
  Light snuff users (<5 box/week) 121/115 0.78 (0.53-1.14) 22/46 0.83 (0.41-1.71) 
  Heavy snuff users (≥5 box/week) 46/29 0.92 (0.49-1.72) 16/26 1.01 (0.42-2.41) 
  <10 box -year 105/104 0.77 (0.52-1.15) 13/39 0.74 (0.31-1.77) 
  ≥10 box -year 60/36 1.00 (0.57-1.74) 22/32 1.00 (0.47-2.11) 
LADA     
  Never 66/223 Reference 70/254 Reference 
  Current  32/92 1.08 (0.64-1.80) 13/41 0.98 (0.45-2.11) 
  Light snuff users (<5 box/week) 29/115 0.76 (0.46-1.27) 10/46 0.75 (0.34-1.67) 
  Heavy snuff users (≥5 box/week) 16/29 1.64 (0.80-3.35) 6/26 0.67 (0.24-1.86) 
  <10 box -year 23/104 0.67 (0.39-1.16) 5/39 0.46 (0.16-1.31) 
  ≥10 box -year 22/36 1.82 (0.96-3.46) 11/32 1.01 (0.45-2.29) 
HUNT     
Type 2 diabetes     
  Never 488/7807 Reference 184/7019 Reference 
  Ever  130/3998 0.86 (0.70-1.07) 27/1779 1.12 (0.72-1.72) 
  Light snuff users (<3 box/week) 107/3521 0.82 (0.65-1.03) 23/1552 1.15 (0.72-1.82) 
  Heavy snuff users (≥3 box/week) 7/262 0.90 (0.41-2.00) 2/176 0.89 (0.21-3.78) 
α
 Adjusted for age, BMI, and family history of diabetes; and also for pack-year of smoking in ever-smokers 
β
 OR for analysis based on ESTRID; and POR for analyses based on HUNT 
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Table 5. OR of LADA and type 2 diabetes for different combinations of smoking and moist 
snuff use, results from ESTRID, 2010-2015. 
Tobacco use  Type 2 diabetes LADA 
No. 
controls 
No. 
cases 
OR 
(95% CI) 
α
 
No. 
cases  
OR 
(95% CI) 
α
 
None 254 205 Reference 70 Reference 
Ever smoking (never snuff) 223 310 1.59 (1.16-2.18) 66 1.06 (0.71-1.57) 
Ever snuff (never smoking) 72 38 0.95 (0.55-1.66) 17 0.74 (0.40-1.39) 
Ever smoking and snuff use 150 171 1.16 (0.81-1.66) 47 0.97 (0.62-1.52) 
Heavy smoking, ≥20 
cigarette/day  (never snuff use) 
54 119 2.20 (1.40-3.45) 27 1.48 (0.84-2.62) 
Heavy smoking and snuff use 46 66 1.45 (0.83-2.51) 21 1.44 (0.78-2.66) 
α
 Adjusted for age, BMI, and family history of diabetes 
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6 DISCUSSION  
6.1 MAIN FINDINGS 
This doctoral thesis aimed to contribute to a better understanding of the association between 
tobacco use and alcohol consumption and the risk of LADA and type 2 diabetes. Identifying 
risk factors for LADA does not only contribute with information that may eventually be 
useful for prevention, but also contributes to understanding of the pathogenesis of LADA.   
The findings indicate that alcohol consumption is associated with reduced risk of more type 
2-like LADA. The possible beneficial effect appears to be mediated through improved insulin 
sensitivity rather than an immune-modulating effect as there was no indication of a beneficial 
effect of alcohol on autoimmunity or LADA with high GADA-levels. With regard to 
smoking, this thesis provided inconsistent but somewhat interesting, results; A reduced risk 
of LADA was seen in smokers in the Norwegian study, whereas in the Swedish study, there 
was no indication of a reduced risk. In contrast, heavy smokers had an increased risk of 
LADA. Given the hybrid pathogenesis of LADA, including both autoimmunity and insulin 
resistance, it is plausible that smoking has both positive (by way of reducing autoimmunity) 
and negative (promoting insulin resistance) effects on development of LADA. Which of these 
effects that dominates may depend on phenotypic or genetic characteristics of the individual. 
Finally, the results indicated that moist snuff, a smokeless tobacco product with high nicotine 
content, is unrelated to the risk of type 2 diabetes and LADA. This suggests that the increased 
risk of type 2 diabetes (and LADA) seen in smokers is not attributed primarily to nicotine 
exposure but to other components of tobacco smoke. 
6.1.1 Alcohol  
The findings from the HUNT study, although based on few patients, suggested that moderate 
intake of alcohol is associated with a reduced risk of LADA. We could confirm and extend 
these findings with data from ESTRID, where we also found that this association was limited 
to the risk of LADA with low GADA (more type 2-like diabetes). With regard to type 2 
diabetes, our findings confirm a similar risk reduction associated with moderate drinking as 
seen in other studies (40; 174; 175).  
The possible mechanisms behind a beneficial effect of alcohol consumption could be 
improved insulin sensitivity (110-113), anti-inflammatory effects (115; 116), and increasing 
adiponectin levels (117-120). In line with this we found an inverse association between 
alcohol consumption and HOMA-IR both in patients with LADA and type 2 diabetes, 
suggesting also that the results are due to the same underlying mechanism. Some 
experimental studies indicate that alcohol has anti-inflammatory and immune-modulating 
properties (176), and this may explain the adverse association between alcohol and some 
autoimmune diseases like rheumatoid arthritis, Graves’ hyperthyroidism, multiple sclerosis, 
and lupus erythematous (124-126; 177; 178). However, findings are inconsistent as other 
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studies did not find evidence of any beneficial effect on autoimmunity (179-181), consistent 
with our studies.  
In line with some previous studies (121; 182), the reduced risk of LADA and type 2 diabetes 
was primarily associated with intake of wine rather than other alcoholic beverages. One 
possible explanation could be that wine contains other substances, like polyphenols and 
antioxidants that may also have beneficial effects, rather than only ethanol. Also, wine 
drinking may be related to a healthier lifestyle behavior in general, particularly with regard to 
diet and socioeconomic factors, compared with drinking spirit and beer (121). Our data 
confirm other studies (108; 182) also suggest that frequent drinking is associated with 
reduced risk of both LADA and type 2 diabetes, irrespective of the amount of alcohol 
consumption.  
6.1.2 Smoking   
We could confirm previous studies showing a positive and dose-dependent association 
between smoking and the risk of type 2 diabetes (41). With regard to LADA, results based on 
HUNT and ESTRID were contradictory; with prospective data from HUNT we found an 
inverse association between smoking and the risk of LADA. In contrast, with data from 
ESTRID including more than twice as many cases, we did not find any indication of 
beneficial effect of smoking on LADA; we even observed an increased risk of LADA in 
heavy smokers. Methodological differences could contribute to the conflicting results. 
Notably, the cut-off level of GADA positivity was higher in HUNT than in ESTRID. 
However, raising the cut-off level in ESTRID did not change the results. The main analysis of 
HUNT did not distinguish between LADA and type 1 diabetes with adult onset, but still, 
restricting the analysis to LADA patients (without insulin treatment during the first year after 
diagnosis) yielded similar result. With regard to information on smoking, due to prospective 
design of HUNT any misclassification of exposure can be assumed non-differential and 
hence unlikely to result in spurious associations. However, the use of baseline information on 
smoking implies that changes in smoking habits that occur during follow-up can not be taken 
into account. In ESTRID on the other hand, information on smoking was collected 
retrospectively until the year of diagnosis and can thus be expected to cover the etiologically 
relevant period. However, this information was retrospective and recall bias, e.g. patients 
overestimating past smoking could have contributed to the excess risk.  
There are mechanistic evidences that are compatible with both beneficial and harmful effects 
of smoking on glucose homeostasis. The increased risk of type 2 diabetes in smokers has 
primarily been attributed to an insulin resistance-inducing effect of nicotine (139; 140). 
However, it has been suggested that smoking (or some compounds in cigarette smoke) can 
also exert immune-modulating and anti-inflammatory effects (144; 145); these potential 
effects are still controversial (144-147; 183) (figure 8). The seemingly contradictory findings 
of our two studies are compatible with the heterogeneous nature of LADA (184); a reduced 
risk can be attributed to exposure of nicotine and its anti-inflammatory and immune-
modulating effect, and an increased risk could be linked to insulin resistance-inducing effect 
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of smoking. In line with this, smoking was associated with lower GADA levels both in 
ESTRID and in HUNT. The net effect of these possible positive and negative mechanisms 
may vary in different LADA patient populations with variable degrees of autoimmunity and 
insulin resistance.  
Findings in other autoimmune disorders, including type 1 diabetes are also contradictory 
(124-126; 178; 185); A reduced risk of type 1 diabetes has been observed in offspring of 
smokers (103-105), whereas a recent Swedish study reported an increased risk of type 1 
diabetes in offspring of smoking mothers, when genetic susceptibility of HLA-haplotype was 
taken into account (186). The influence of genetic factors may indeed contribute to the 
seemingly inconsistent results; A very strong interaction between smoking and HLA-
haplotype has been identified in relation to rheumatoid arthritis (187). HLA-haplotype is also 
associated with the risk of type 1 diabetes and LADA, so one could speculate that the 
influence of smoking on autoimmune diabetes is modified by genetic factors, which remains 
to be explored. In this context it is noteworthy that with regard to genetic factors the LADA 
population in HUNT seems to be more type 1-like (90) than the Swedish LADA population 
in Scania (20; 188). 
 
Figure 8. Summary of the acute effects of cigarette smoking; data extracted from human, 
animal, and in vitro studies. Adapted from van der Vaart, H. et al. (183) 
6.1.3 Moist snuff use 
In contrast to findings regarding cigarette smoking, we found no association between moist 
snuff use and the risk of type 2 diabetes and LADA, this supports findings of one out three 
small previous studies in type 2 diabetes (136; 151; 152). Our findings also fit with studies 
of tobacco use in relation to the risk of circulatory diseases such as stroke and myocardial 
infarction (189-191), where a smaller risk increase is observed in moist snuff users 
 32 
compared to smokers. For LADA our findings are consistent with observations made in 
other autoimmune diseases including rheumatoid arthritis (192) and Crohn’s disease (193) 
in relation to moist snuff use. This suggest that noxious substances in cigarette smoke other 
than nicotine, such as nitrosamine, are likely to be involved in etiology of type 2 diabetes 
(194), and moist snuff provides less exposure to toxins than cigarette smoking. Importantly, 
we did not have enough power to rule out a small effect of moist snuff use on type 2 
diabetes, and this notion remains to be addressed in larger studies.   
6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Non-response 
The participation rate at the first survey of HUNT was high, but it declined at HUNT 2 and 
HUNT3 surveys. However, the non-participations studies for HUNT surveys did not find 
significant difference according to health and mortality, except for elderly non-participants 
who had higher morbidity compared to participants in that age (102; 158). 
Loss to follow-up may be a problem in longitudinal studies and lead to selection bias if there 
is a differential loss to follow-up related to exposure and outcome.  In HUNT, participants 
were lost either because they died or because they discontinued their participation. Loss to 
follow-up could introduce bias in studies I and III, if it was related to both diabetes and 
alcohol consumption/smoking. In order to check the potential influence of loss to follow-up 
we compared the average daily alcohol consumption among those lost with those individuals 
remaining in the study, and no considerable difference was found (3.70 vs. 3.90 gram/day). 
Neither did we see any substantial difference across categories of smoking (current smoking: 
34% vs 33%; heavy smoking: 8% vs. 9%) among those who re-attended compared to those 
lost to follow-up. However, if we assume that individuals with high alcohol consumption, if 
they developed diabetes, were more likely to die from it before follow-up, this could lead us 
to overestimate a proposed beneficial effect of alcohol consumption. Following the same line 
of reasoning, smokers who develop diabetes may be more likely to die, or chose not to 
participate in the follow-up survey. One consequence could be an overestimation of the 
reduced risk of LADA related to smoking. It is however hard to see how such a bias would 
yield contrasting results for LADA and type 2 diabetes.   
In case-control studies, controls are used to estimate the prevalence of exposure in the 
population which produced the cases. In ESTRID, we selected controls randomly and 
continuously from the same population as the cases originated from according to classical 
case-control methodology (168). Participation rates were relatively high among cases and 
controls (81% vs. 66%).  Still, if consumption of alcohol, cigarettes, or moist snuff among 
participating controls was different from those who did not choose to participate, this would 
bias our findings. In the ESTRID controls prevalence of smoking, moist snuff use and alcohol 
consumption was comparable with what has been reported by the Public Health Agency of 
Sweden for the population living in Scania (148). Furthermore, the similarities of our findings 
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regarding type 2 diabetes with previous prospective studies (41; 182), is an important 
indicator of the validity of the controls. 
6.2.2 Misclassification of Exposure 
A high correlation between self-reported smoking data and cotinine levels (biomarker of 
exposure to tobacco) has been shown (195; 196). It has also been demonstrated that self-
reported alcohol consumption correlates with biomarkers, and furthermore, that using 
beverage-specific questions increases the validity of the self-reports (200). Still, the 
probability of bias in self-reported information on lifestyle cannot be ruled out (197; 198). In 
HUNT, misclassification can be assumed to be non-differential, i.e. not affected by disease 
status, and will hence tend to dilute a true association, distort dose-response relationships, but 
is unlikely to result in spurious excess risks (199). A baseline assessment of alcohol intake 
may not be enough to get an accurate picture of exposure status over the whole time at risk 
and this may dilute the associations. In our study population, abstainers at least did not 
change their consumption: 86% of abstainers at the beginning of HUNT1 remained abstainers 
at HUNT2. With regard to smoking we had the advantage of repeated assessments in HUNT, 
which limits misclassification. 
In ESTRID, information on alcohol and smoking was based on retrospective self-reporting. 
This implies that bias is introduced e.g. if people with diabetes changed their consumption 
after diagnosis and reported accordingly. To minimize this potential bias, cases received the 
questionnaire close to diagnosis with instructions to report their habits as they were before 
diagnosis. Importantly, in current dietary guidelines in Sweden, there is no recommendation 
about changing alcohol consumption for patients with diabetes (40). For smoking and moist 
snuff use, to minimize the problem of reverse causation (disease affecting smoking habits), 
we only included information on tobacco use until the index year, which was one year before 
diagnosis. It should also be noted that our results for type 2 diabetes in relation to both 
alcohol and smoking were in close agreement with findings from several prospective studies 
(41; 182), where exposure information was collected several years before onset of disease.  
In study V, we used cross-sectional HUNT data, hence, recall bias is a potential problem as 
patients may have quit using tobacco several years ago following diagnosis or shift from 
smoking to snuffing. We did use information about previous tobacco habits, but it is 
possible that those who quit underestimate their previous use. 
One of the concerns in alcohol consumption related observational studies is known as “Sick 
quitter” bias. According to this notion abstainers are not an appropriate reference group 
because it is possible that some people abstain from alcohol for health reasons, or because 
they are taking some prescribed drugs that interact with alcohol or, because they are former 
heavy drinkers (200). Notably, we found a reduced diabetes risk of in moderate consumers, 
irrespective of whether abstainers or very low consumers were used as reference category. 
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6.2.3 Misclassification of disease 
An important requirement for any epidemiological study is a set of well-defined diagnostic 
criteria. In HUNT, diabetes cases were identified by self-report. A validation done previously 
among HUNT participants indicated a very high concordance between questionnaire data and 
medical records (159). Still, cases of undiagnosed diabetes will be missed. If undiagnosed 
diabetes is more common in individuals with low socioeconomic status which is also related 
to behaviors like high alcohol consumption and smoking, potential bias could occur. 
However, it has been reported that undiagnosed diabetes is uncommon (0.3%) in participants 
of HUNT (201), and the influence of this potential bias is probably minor.  Cases included in 
ESTRID were identified and diagnosed through the public health system. It is possible that 
some of the cases may have undiagnosed diabetes, and if so, this will tend to make them 
more similar to the cases and most probably lead to a dilution of the associations between 
lifestyle and diabetes risk.  
The diabetes patients were classified into different types based on information about age at 
onset and GADA levels. Sensitivity of the GADA assays were 64-84% which means that 
some cases of LADA was missed and this reduces power but is otherwise unlikely to affect 
the results. With regard to specificity, it was 100% in HUNT which means that cases of type 
2 diabetes are unlikely to be classified as LADA. Hence, this potential misclassification does 
not seem to be a probably explanation for the similarity of alcohol results seen for type 2 
diabetes and LADA. However, in ESTRID the specificity of the GADA assay was 98%, 
implying the possibility of false-positive LADA cases (type 2 diabetes patients misclassified 
as having LADA), which could account for some of the similarities of alcohol consumption 
results seen between LADA with low GADA and type 2 diabetes. It is however unlikely to 
explain the lack of association observed between alcohol intake and LADA with high 
GADA. Also, misclassification of cases may have contributed to the similar smoking results 
for LADA and type 2 diabetes; If we assume that 24 (2%) of the type 2 diabetes patients are 
misclassified as having LADA, and all of them were heavy smokers, this would result in an 
attenuation of the association (OR of LADA for ≥15 pack-year estimated at 1.10). Still, this 
seems highly unlikely and furthermore, this potential misclassification could not explain why 
we find no indication of a beneficial effect of smoking on LADA in ESTRID. 
In our studies, only GADA measurements were available as an indicator of autoimmunity 
and we may therefore be missing LADA patients who are positive for other autoantibodies 
such as like IAA, and ICA. GADA is however the most sensitive maker for autoimmune 
diabetes in adults and is present in 70–80% of patients with autoimmune diabetes (94). 
Furthermore, it was recently shown in the HUNT Study that only 10% of LADA cases were 
positive for other antibodies than GADA (202) 
6.2.4 Confounding 
An advantage was that we had access to detailed information about many potential 
confounders including smoking, BMI, physical activity, family history of diabetes, alcohol 
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consumption, and education. The possibility of remaining residual confounding or 
confounding from unmeasured factors still needs to be considered while interpreting the 
results. In this context it is noteworthy that with regard to analyses of alcohol in ESTRID, 
further adjustment for intake of coffee and soft drinks, as well as total energy intake (data 
now shown in the paper), did not alter the results.  
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7 CONCLUSION 
This thesis includes studies of alcohol consumption and tobacco use, two common, 
modifiable lifestyle factors, in relation to the risk of LADA. The findings indicate that alcohol 
may have a beneficial effect on the risk of LADA particularly for more type 2-like LADA, as 
shown previously for type 2 diabetes. The influence of smoking was contradictory with a 
reduced risk of LADA in the Norwegian study, and an increased risk of LADA in the 
Swedish study. With regard to moist snuff use, no association was found with type 2 diabetes 
and LADA, this supports data suggesting that moist snuff is less harmful than other tobacco 
products (189-191; 194; 203).  
Overall these findings indicate that LADA and type 2 diabetes may have a partly shared 
etiology, including insulin resistance. It is possible that in the presence of mild autoimmunity, 
improvements (alcohol) or impairment (smoking) of insulin sensitivity will accelerate or 
postpone development of manifest diabetes. The contradictory findings of smoking and the 
different results seen for LADA with high and low GADA levels support the concept of 
heterogeneity of LADA. Hence, it is possible that the effect of environmental triggers on the 
risk of LADA depends on interaction with genetic factors and/or the severity of the 
underlying autoimmune process.  
The findings of the thesis fit with previous observations in LADA (79-86) and indicate that 
lifestyle factors may be important for prevention of LADA. Confirmation of these findings in 
other populations are warranted and there are many questions that remain to be addressed 
including both the role of individual lifestyle factors, the interaction between sets of potential 
risk factors and the interaction between lifestyle and genetic factors.  
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8 FUTURE DIRECTIONS 
- Most studies on risk factors of LADA are based on Scandinavian populations. Studies in 
other ethnic groups and populations with different genetic disposition and clinical 
characteristics are clearly needed.  
- The risk factors of LADA are largely unexplored, and many aspects remain to be addressed, 
including factors such as early life exposures, dietary factors and exposure to environmental 
toxins. 
- Environmental factors are likely to interact with genetic factors in development of LADA 
but this remains to be explored, including interaction between smoking and genetic risk 
factors  
- Factors that lead to epigenetic variation over time through DNA methylation (e.g. exposure 
to toxins), are also interesting to explore in future studies.  
- There is a lack of studies on long term consequences of LADA including the risk of macro-
and microvascular complications. 
- The optimal treatment of LADA remains to be established.    
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